Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Johnson and Johnson
Colorcon
Deloitte
Cerilliant
McKinsey
Cantor Fitzgerald
AstraZeneca
Express Scripts

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,173,942

« Back to Dashboard

Which drugs does patent 9,173,942 protect, and when does it expire?


Patent 9,173,942 protects ALOXI and is included in one NDA.

Protection for ALOXI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in forty countries.

Summary for Patent: 9,173,942

Title:Liquid pharmaceutical formulations of palonosetron
Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
Inventor(s): Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Casalzuigno, IT), Cannella; Roberta (Varese, IT), Macciocchi; Alberto (Melide, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M (Palo Alto, CA)
Assignee: HELSINN HEALTHCARE SA (Pambio-Noranco, CH) Roche Palo Alto LLC (Palo Alto, CA)
Application Number:13/901,830
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-002Feb 29, 2008APRXYesYes► Subscribe► SubscribeY
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,173,942

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,598,218Liquid pharmaceutical formulations of palonosetron► Subscribe
9,457,021Liquid pharmaceutical formulations of palonosetron► Subscribe
7,947,724Liquid pharmaceutical formulations of palonosetron► Subscribe
9,066,980Liquid pharmaceutical formulations of palonosetron► Subscribe
9,125,905Liquid pharmaceutical formulations of palonosetron► Subscribe
7,960,424Liquid pharmaceutical formulations of palonosetron► Subscribe
9,457,020Liquid pharmaceutical formulations of palonosetron► Subscribe
8,518,981Liquid pharmaceutical formulations of palonosetron► Subscribe
8,598,219Liquid pharmaceutical formulations of palonosetron► Subscribe
7,947,725Liquid pharmaceutical formulations of palonosetron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,173,942

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)2110► Subscribe
Argentina042977► Subscribe
Austria410167► Subscribe
Australia2004208505► Subscribe
BrazilPI0407121► Subscribe
Canada2514224► Subscribe
Canada2573194► Subscribe
Canada2573228► Subscribe
Canada2573241► Subscribe
Canada2573363► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Farmers Insurance
US Department of Justice
UBS
Colorcon
Fuji
Accenture
AstraZeneca
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot